Respiratory syncytial virus (RSV) causes significant morbidity and mortality in infants worldwide. Although prematurity and cardiopulmonary disease are risk factors for severe disease, the majority of infants hospitalized with RSV are previously healthy. Various vaccines and therapeutics are under development and expected to be available in the near future. To inform the use of these new vaccines and therapeutics, it is necessary to determine the burden of RSV disease in Europe. We will prospectively follow-up a birth cohort to obtain incidence data on RSV acute respiratory tract infection (ARTI).

中文翻译：

---

欧洲呼吸道合胞病毒协会（RESCEU）出生队列研究：确定欧洲婴儿呼吸道合胞病毒病的负担。

呼吸道合胞病毒（RSV）导致全世界婴儿的严重发病和死亡。尽管早产和心肺疾病是严重疾病的风险因素，但大多数因RSV住院的婴儿以前都是健康的。各种疫苗和治疗剂正在开发中，预计将在不久的将来上市。为了告知这些新疫苗和治疗剂的使用，有必要确定欧洲RSV疾病的负担。我们将对出生队列进行前瞻性随访，以获取有关RSV急性呼吸道感染（ARTI）的发病率数据。